GE, Immunomedics collaborate on F-18 peptide labeling
Immunomedics and GE Healthcare have entered into a license and collaboration agreement for the evaluation of labeling technologies based on Immunomedics' patented F-18 peptide labeling method.

Terms of the agreement were not disclosed, but GE Healthcare will fund all costs related to this collaboration, said Morris Plains, N.J.-based Immunomedics.

Immunomedics said its labeling method of binding F-18 to peptides via an aluminum conjugate is protected by two patents in the U.S., and under prosecution in major world markets. F-18 labeled peptides have been shown to be stable enough to produce quality PET images of receptor-expressing tumors in animals and in pretargeting studies using a human colorectal cancer model, added the company.